New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
11:02 EDTALXNAlexion:Data show substantial improvement with Soliris in patients with STEC-HUS
Alexion Pharmaceuticals announced the presentation of 28-week data from all enrolled patients in a multi-center trial of eculizumab, Soliris, in patients who developed Shiga-toxin-producing E. coli hemolytic uremic syndrome, STEC-HUS, during an outbreak in Germany from May 2011 to July 2011. In the study, eculizumab therapy was associated with rapid and sustained clinical improvements in thrombotic microangiopathy, TMA, and systemic organ complications. The study met its primary endpoint of global assessment of efficacy at 8 weeks with 94% of patients achieving a complete or partial response in systemic TMA and vital organ involvement. Key secondary endpoints were also met with high clinical and statistical significance, including global assessment of efficacy at 28 weeks as well as improvement in hematologic, renal and neurologic functions. Preliminary findings from an exploratory post hoc, matched-control analysis of patients with severe STEC-HUS receiving eculizumab versus other patients who received current best supportive care during the German epidemic were also reported, and showed that eculizumab treatment was associated with consistently higher rates of renal and neurological function improvement at weeks 8 and 28.1
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
07:44 EDTALXNAlexion valuation looking increasingly compelling, says Stifel
Subscribe for More Information
July 24, 2014
11:53 EDTALXNAlexion price target raised to $214 from $196 at Piper Jaffray
Subscribe for More Information
06:43 EDTALXNAlexion raises 2014 adjusted EPS view to $4.95-$5.05 from $4.75-$4.85
Subscribe for More Information
06:41 EDTALXNAlexion reports Q2 adjusted EPS $1.12, consensus $1.07
Subscribe for More Information
06:17 EDTALXNAlexion's hypophosphatasia candidate MAA accepted by European Medicines Agency
Subscribe for More Information
July 22, 2014
11:48 EDTALXNStocks with call strike movement; EXPE ALXN
Subscribe for More Information
July 16, 2014
10:01 EDTALXNPegasystems appoints Warner Chief Compliance Officer
Subscribe for More Information
08:01 EDTALXNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use